<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; investments</title>
	<atom:link href="http://www.tapanray.in/tag/investments/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Why Pharma Need To Connect Better With Patient Organizations Now?</title>
		<link>http://www.tapanray.in/pharma-need-to-connect-with-patient-organizations-more-than-ever-before/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-need-to-connect-with-patient-organizations-more-than-ever-before</link>
		<comments>http://www.tapanray.in/pharma-need-to-connect-with-patient-organizations-more-than-ever-before/#comments</comments>
		<pubDate>Mon, 09 Aug 2021 00:00:02 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[commercially]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Connect]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[deliver]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[end-to-nd]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[group]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[low]]></category>
		<category><![CDATA[maximize]]></category>
		<category><![CDATA[need]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Organizations]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[player]]></category>
		<category><![CDATA[Pos]]></category>
		<category><![CDATA[Programms]]></category>
		<category><![CDATA[PSG]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[return]]></category>
		<category><![CDATA[services]]></category>
		<category><![CDATA[Suppor]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[usage]]></category>
		<category><![CDATA[useful]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10564</guid>
		<description><![CDATA[A good number of patients (63%), especially those with chronic ailments would look for Patient Support Services, revealed a survey by Human Healthcare Systems, released on February 25, 2020. Alongside, drug companies are also, reportedly, investing billions of dollars in every year, for several types of &#8230; <a href="http://www.tapanray.in/pharma-need-to-connect-with-patient-organizations-more-than-ever-before/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-need-to-connect-with-patient-organizations-more-than-ever-before/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patented Drug Pricing: Relevance To R&amp;D Investments</title>
		<link>http://www.tapanray.in/patented-drug-pricing-relevance-to-rd-investments/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patented-drug-pricing-relevance-to-rd-investments</link>
		<comments>http://www.tapanray.in/patented-drug-pricing-relevance-to-rd-investments/#comments</comments>
		<pubDate>Mon, 18 Aug 2014 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[AMP]]></category>
		<category><![CDATA[brain]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relevance R&D]]></category>
		<category><![CDATA[smarter]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5766</guid>
		<description><![CDATA[The costs of most of the new life saving drugs, used in the treatment of dreaded diseases such as cancer, have now started going north at a brisk pace, more than ever before. From the global pharma industry perspective, the &#8230; <a href="http://www.tapanray.in/patented-drug-pricing-relevance-to-rd-investments/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patented-drug-pricing-relevance-to-rd-investments/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma FDI Debate: Highly Opinionated, Sans Assessment of Tangible Outcomes?</title>
		<link>http://www.tapanray.in/pharma-fdi-debate-highly-opinionated-sans-assessment-of-tangible-outcomes/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-fdi-debate-highly-opinionated-sans-assessment-of-tangible-outcomes</link>
		<comments>http://www.tapanray.in/pharma-fdi-debate-highly-opinionated-sans-assessment-of-tangible-outcomes/#comments</comments>
		<pubDate>Mon, 18 Nov 2013 00:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[addition]]></category>
		<category><![CDATA[assessment]]></category>
		<category><![CDATA[asset]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[FIPB]]></category>
		<category><![CDATA[Fixed]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[ilk]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[job]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[Opinionated]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[shorn]]></category>
		<category><![CDATA[tangible]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[wage]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4217</guid>
		<description><![CDATA[In 2001, the Government of India (GoI) allowed 100 percent Foreign Direct Investments (FDI) in the pharmaceutical sector through automatic route to attract more investments for new asset creation, boost R&#38;D, new job creation and ultimately to help aligning Indian &#8230; <a href="http://www.tapanray.in/pharma-fdi-debate-highly-opinionated-sans-assessment-of-tangible-outcomes/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-fdi-debate-highly-opinionated-sans-assessment-of-tangible-outcomes/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>R&amp;D: Is Indian Pharma Moving Up the Value Chain?</title>
		<link>http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=rd-is-indian-pharma-moving-up-the-value-chain</link>
		<comments>http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/#comments</comments>
		<pubDate>Mon, 02 Sep 2013 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[agreement]]></category>
		<category><![CDATA[analogue]]></category>
		<category><![CDATA[arbitrage]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[bharat]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[Brownfield]]></category>
		<category><![CDATA[Cadilla]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[collaboration]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[critical]]></category>
		<category><![CDATA[CSIR]]></category>
		<category><![CDATA[DBT]]></category>
		<category><![CDATA[deal]]></category>
		<category><![CDATA[diabetic]]></category>
		<category><![CDATA[Dr]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[dyslipidemia]]></category>
		<category><![CDATA[ecosystem]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[falciparum]]></category>
		<category><![CDATA[Forest]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[giant]]></category>
		<category><![CDATA[Glenmark]]></category>
		<category><![CDATA[Glitazar]]></category>
		<category><![CDATA[hibernation]]></category>
		<category><![CDATA[ICMR]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[Jubilant]]></category>
		<category><![CDATA[lab]]></category>
		<category><![CDATA[Leap]]></category>
		<category><![CDATA[Licensing]]></category>
		<category><![CDATA[Lipaglyn]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[malaria]]></category>
		<category><![CDATA[mass]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Piramal]]></category>
		<category><![CDATA[plasmodium]]></category>
		<category><![CDATA[private]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reddy's]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Rotavac]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[sector]]></category>
		<category><![CDATA[small]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[Synrium]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Torrent]]></category>
		<category><![CDATA[universities]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[wockhardt]]></category>
		<category><![CDATA[Zydus]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3530</guid>
		<description><![CDATA[It almost went unnoticed by many, when in the post product patent regime, Ranbaxy launched its first homegrown ‘New Drug’ of India, Synriam, on April 25, 2012, coinciding with the ‘World Malaria Day’. The drug is used in the treatment &#8230; <a href="http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma FDI: Damning Report of Parliamentary Panel, PM Vetoes&#8230;and Avoids Ruffling Feathers?</title>
		<link>http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers</link>
		<comments>http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/#comments</comments>
		<pubDate>Mon, 19 Aug 2013 00:00:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[acquisitions]]></category>
		<category><![CDATA[addition]]></category>
		<category><![CDATA[Approach]]></category>
		<category><![CDATA[BRIC]]></category>
		<category><![CDATA[Brownfield]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Commerce]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[Daiichi]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[Discussion]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[feathers]]></category>
		<category><![CDATA[FIPB]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[illusionary]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[matrix]]></category>
		<category><![CDATA[mergers]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[MNCs]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[oligopolistic]]></category>
		<category><![CDATA[Paper]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Piramal]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[PMO]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[protectionism]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[restriction]]></category>
		<category><![CDATA[retrograde]]></category>
		<category><![CDATA[ruffling]]></category>
		<category><![CDATA[Sankyo]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tweaking]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[vetoed]]></category>
		<category><![CDATA[vetoes veto]]></category>
		<category><![CDATA[wrong]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3241</guid>
		<description><![CDATA[An interesting situation emerged last week. The Parliamentary Standing Committee (PSC) on Commerce proposed a blanket ban on all FDI in brownfield pharma sector. Just two days after that, the Prime Minister of India vetoed the joint opposition of the Department &#8230; <a href="http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>An El Dorado&#8230;But Not Without Responsible Pricing:The Cancer Segment in India</title>
		<link>http://www.tapanray.in/right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area</link>
		<comments>http://www.tapanray.in/right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area/#comments</comments>
		<pubDate>Mon, 04 Feb 2013 00:00:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[area]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[breast]]></category>
		<category><![CDATA[British]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cervical]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Eldorado]]></category>
		<category><![CDATA[female]]></category>
		<category><![CDATA[gold]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[hamied]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[lung]]></category>
		<category><![CDATA[male]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Natco]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPP2012]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[oral]]></category>
		<category><![CDATA[ovarian]]></category>
		<category><![CDATA[ovary]]></category>
		<category><![CDATA[pancreatic]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[pot]]></category>
		<category><![CDATA[pots]]></category>
		<category><![CDATA[PPP]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[responsible]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[rural]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[segment]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[urban]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[yusuf]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=1493</guid>
		<description><![CDATA[The affordability issue for cancer treatment has been the subject of a raging debate since quite some time, as the incidence of cancer is fast increasing across the world. Just for example a very recent report highlighted that cancer has now become the &#8230; <a href="http://www.tapanray.in/right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Maira Committee’ delivers: Resolves 100% FDI issue in the pharma sector of India</title>
		<link>http://www.tapanray.in/maira-committee-delivers-resolves-100-fdi-issue-in-the-pharma-sector-of-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=maira-committee-delivers-resolves-100-fdi-issue-in-the-pharma-sector-of-india</link>
		<comments>http://www.tapanray.in/maira-committee-delivers-resolves-100-fdi-issue-in-the-pharma-sector-of-india/#comments</comments>
		<pubDate>Mon, 17 Oct 2011 00:00:55 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[100%]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[delivers]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[issue]]></category>
		<category><![CDATA[Maira]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Resolves]]></category>
		<category><![CDATA[sector]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=187</guid>
		<description><![CDATA[On October 10, 2011, Dr Man Mohan Singh, the Prime Minister of India accepted the recommendation of the ‘Maira Committee’ on Foreign Direct Investment (FDI) in the Pharmaceutical Sector of India and decided that the Competition Commission of India (CCI) &#8230; <a href="http://www.tapanray.in/maira-committee-delivers-resolves-100-fdi-issue-in-the-pharma-sector-of-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/maira-committee-delivers-resolves-100-fdi-issue-in-the-pharma-sector-of-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Seeing ghosts where there aren&#8217;t any</title>
		<link>http://www.tapanray.in/seeing-ghosts-where-there-arent-any/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=seeing-ghosts-where-there-arent-any</link>
		<comments>http://www.tapanray.in/seeing-ghosts-where-there-arent-any/#comments</comments>
		<pubDate>Mon, 10 Oct 2011 00:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[any]]></category>
		<category><![CDATA[aren't]]></category>
		<category><![CDATA[attractive]]></category>
		<category><![CDATA[chris]]></category>
		<category><![CDATA[ghosts]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Seeing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[there]]></category>
		<category><![CDATA[viebachar]]></category>
		<category><![CDATA[where]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=190</guid>
		<description><![CDATA[Seeing ghosts almost everywhere in the Indian pharmaceutical industry, especially where there aren&#8217;t any, has indeed become quite common nowadays, across the spectrum of stakeholders. The ‘ghosts’ could well reside in ‘100% Foreign Direct Investments (FDI) through automatic route in &#8230; <a href="http://www.tapanray.in/seeing-ghosts-where-there-arent-any/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/seeing-ghosts-where-there-arent-any/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDI in ‘Brownfield’ Pharma acquisitions and the growth of ‘Greenfield’ projects in India</title>
		<link>http://www.tapanray.in/fdi-in-brownfield-pharma-acquisitions-and-the-growth-of-greenfield-projects-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=fdi-in-brownfield-pharma-acquisitions-and-the-growth-of-greenfield-projects-in-india</link>
		<comments>http://www.tapanray.in/fdi-in-brownfield-pharma-acquisitions-and-the-growth-of-greenfield-projects-in-india/#comments</comments>
		<pubDate>Sat, 17 Sep 2011 00:30:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[100%]]></category>
		<category><![CDATA[49%]]></category>
		<category><![CDATA[acquisitions]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Brownfield]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[Greenfield]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[projects]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=200</guid>
		<description><![CDATA[Just when global multinational companies are inking deals to get more and more drugs manufactured in India, because of various financial and other considerations, giving a fillip to the domestic manufacturing capacity, recent media reports are carrying news items expressing &#8230; <a href="http://www.tapanray.in/fdi-in-brownfield-pharma-acquisitions-and-the-growth-of-greenfield-projects-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/fdi-in-brownfield-pharma-acquisitions-and-the-growth-of-greenfield-projects-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharmaceutical R&amp;D in India: Issues and Challenges</title>
		<link>http://www.tapanray.in/pharmaceutical-rd-in-india-issues-and-challenges/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharmaceutical-rd-in-india-issues-and-challenges</link>
		<comments>http://www.tapanray.in/pharmaceutical-rd-in-india-issues-and-challenges/#comments</comments>
		<pubDate>Mon, 15 Aug 2011 00:30:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=215</guid>
		<description><![CDATA[Research and Development (R&#38;D) initiatives, though very important for most of the industries, is the life blood for the pharmaceutical sector, across the globe, to meet the unmet needs of the patients. Thus, very rightly, the Pharmaceutical Industry is considered &#8230; <a href="http://www.tapanray.in/pharmaceutical-rd-in-india-issues-and-challenges/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharmaceutical-rd-in-india-issues-and-challenges/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
